Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2015

01-02-2015 | Review Article

Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review

Authors: Sang Hui Chu, Young Joo Lee, Eon Sook Lee, Yimin Geng, Xin Shelley Wang, Charles S. Cleeland

Published in: Supportive Care in Cancer | Issue 2/2015

Login to get access

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) is common among cancer patients who undergo chemotherapy with platinum analogues, taxanes, vinca alkaloids, epothilone, bortezomib, and thalidomide. The purpose of this study was to investigate the evidence of using drugs affecting the central nervous system (CNS) to alleviate CIPN in cancer patients.

Methods

A systematic literature search was conducted using the CINAHL, EMBASE, and Medline databases to identify randomized controlled clinical trials (RCTs) reported in English up to 2013. We identified ten trials of CNS-acting drugs used to treat CIPN in cancer patients and reviewed efficacy and safety of CNS-acting drugs for CIPN using a standard data collection form. The risk of bias in each RCT was also assessed.

Results

Antidepressants were used in six studies and anticonvulsants in four studies. We found positive results for amitriptyline (topical), venlafaxine, and oxcarbazepine in one study each, but the results were not sufficient to draw definite conclusions. One trial with duloxetine showed a moderate effect (effect size, 0.513, P = .003) on CIPN pain relief. However, none of the results has yet been duplicated in an RCT with a large sample size.

Conclusions

Insufficient RCTs exist to confirm the efficacy of CNS agents to reduce CIPN. This study highlighted the need for and the importance of conducting well-designed RCTs to generate evidence on CIPN symptom management. Additional RCTs are warranted to accelerate the potential use of CNS drugs for CIPN in cancer patients.
Appendix
Available only for authorised users
Literature
1.
Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE et al (2009) NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 7(Suppl 5):S1–S26, quiz S27–28PubMed
2.
Schiff D, Wen PY, van den Bent MJ (2009) Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 6:596–603PubMedCrossRef
3.
Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77PubMedCrossRef
4.
5.
Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38:1832–1837PubMedCrossRef
6.
Garcia de Paredes ML, del Moral GF, Martinez del Prado P, Marti Ciriquian JL, Enrech Frances S et al (2011) First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the On study. Ann Oncol 22:924–930PubMedCrossRef
7.
Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS (1987) Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71:1171–1177PubMed
8.
Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B et al (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113–3120PubMedCrossRef
9.
Speck RM, Sammel MD, Farrar JT, Hennessy S, Mao JJ et al (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9:e234–240PubMedCrossRef
10.
Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G et al (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699–2707PubMedCrossRef
11.
Wen F, Zhou Y, Wang W, Hu QC, Liu YT et al (2013) Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol 24:171–178PubMedCrossRef
12.
Xu XT, Dai ZH, Xu Q, Qiao YQ, Gu Y et al (2013) Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers. J Dig Dis 14:288–298PubMedCrossRef
13.
Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005PubMedCrossRef
14.
Schloss JM, Colosimo M, Airey C, Masci PP, Linnane AW et al (2013) Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review. Clin Nutr 32:888–893
15.
Albers JW, Chaudhry V, Cavaletti G, Donehower RC (2014) Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 3, CD005228
16.
Sultan A, Gaskell H, Derry S, Moore RA (2008) Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol 8:29PubMedCentralPubMedCrossRef
17.
Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P et al (2013) Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev 11, CD010567
18.
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367PubMedCentralPubMedCrossRef
19.
Baron R, Binder A, Wasner G (2010) Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9:807–819PubMedCrossRef
20.
Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90:377–387PubMedCrossRef
21.
Aziz MT, Good BL, Lowe DK (2014) Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 48:626–632PubMedCrossRef
22.
Kautio AL, Haanpaa M, Saarto T, Kalso E (2008) Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manag 35:31–39CrossRef
23.
Kautio AL, Haanpaa M, Leminen A, Kalso E, Kautiainen H et al (2009) Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res 29:2601–2606PubMed
24.
Barton DL, Wos EJ, Qin R, Mattar BI, Green NB et al (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19:833–841PubMedCentralPubMedCrossRef
25.
Hammack JE, Michalak JC, Loprinzi CL, Sloan JA, Novotny PJ et al (2002) Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 98:195–203PubMedCrossRef
26.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F et al (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200–205PubMedCrossRef
27.
Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118PubMedCrossRef
28.
Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P et al (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802–2808PubMedCrossRef
29.
von Delius S, Eckel F, Wagenpfeil S, Mayr M, Stock K et al (2007) Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study. Invest New Drugs 25:173–180CrossRef
30.
Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A et al (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253–2255PubMedCrossRef
31.
Yang YH, Lin JK, Chen WS, Lin TC, Yang SH et al (2012) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer 20:1491–1497PubMedCrossRef
32.
Irwin MR (2013) Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Curr Psychiatry Rep 15:404PubMedCrossRef
33.
Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J et al (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:1941–1967PubMedCrossRef
34.
Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK et al (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3–14PubMedCentralPubMedCrossRef
35.
Vadalouca A, Raptis E, Moka E, Zis P, Sykioti P et al (2012) Pharmacological treatment of neuropathic cancer pain: a comprehensive review of the current literature. Pain Pract 12:219–251PubMedCrossRef
36.
Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA et al (2001) Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21:1868–1875PubMed
37.
Shimoyama M, Shimoyama N, Hori Y (2000) Gabapentin affects glutamatergic excitatory neurotransmission in the rat dorsal horn. Pain 85:405–414PubMedCrossRef
38.
Ross JR, Goller K, Hardy J, Riley J, Broadley K et al (2005) Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study. J Palliat Med 8:1118–1126PubMedCrossRef
39.
Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H et al (2008) Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study. Pain Med 9:1209–1216PubMedCrossRef
40.
Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R et al (2004) Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol 22:2909–2917PubMedCrossRef
41.
Mishra S, Bhatnagar S, Goyal GN, Rana SP, Upadhya SP (2012) A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care 29:177–182PubMedCrossRef
42.
Grisold W, Cavaletti G, Windebank AJ (2012) Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 14(Suppl 4):iv45–54PubMedCentralPubMed
43.
Peng Z, Wang Q, Gao J, Ji Z, Yuan J et al (2013) Association between GSTP1 Ile105Val polymorphism and oxaliplatin-induced neuropathy: a systematic review and meta-analysis. Cancer Chemother Pharmacol 72:305–314PubMedCrossRef
44.
Alberti P, Rossi E, Cornblath DR, Merkies IS, Postma TJ et al (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264PubMedCentralPubMedCrossRef
45.
Griffith KA, Merkies IS, Hill EE, Cornblath DR (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15:314–325PubMedCrossRef
46.
Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E et al (2010) Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479–494PubMedCrossRef
47.
Takenaka M, Iida H, Matsumoto S, Yamaguchi S, Yoshimura N et al (2013) Successful treatment by adding duloxetine to pregabalin for peripheral neuropathy induced by paclitaxel. Am J Hosp Palliat Care 30:734–736PubMedCrossRef
48.
Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028–4029PubMedCrossRef
Metadata
Title
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review
Authors
Sang Hui Chu
Young Joo Lee
Eon Sook Lee
Yimin Geng
Xin Shelley Wang
Charles S. Cleeland
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2408-8

Other articles of this Issue 2/2015

Supportive Care in Cancer 2/2015 Go to the issue

Original Article

Exploring the myths of morphine in cancer: views of the general practice population

Original Article

Factors associated with gastrostomy tube dependence after concurrent chemoradiotherapy for hypopharyngeal cancer

Original Article

Validation of the Holistic Comfort Questionnaire- caregiver in Portuguese-Brazil in a cohort of informal caregivers of palliative care cancer patients

Original Article

Length of home hospice care, family-perceived timing of referrals, perceived quality of care, and quality of death and dying in terminally ill cancer patients who died at home

Original Article

The Spanish version of the Body Image Scale (S-BIS): psychometric properties in a sample of breast and gynaecological cancer patients

Original Article

Peripherally inserted central catheters in non-hospitalized cancer patients: 5-year results of a prospective study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits